Edison Investment Research - VolitionRX (VNRX) VolitionRx - Vetting the pet health opportunity

Report

Edison Investment Research

Sean Conroy

VolitionRx - Vetting the pet health opportunity

While pets are increasingly being ‘humanized’, their healthcare has lagged advancements seen on the human side. With the COVID-19 pandemic accelerating the trend of pet ownership, demand for improved care in a market with limited alternatives has triggered the need for newer-generation pet diagnostics. VolitionRx, a diagnostics company focused on sepsis and cancer detection, has pioneered a low-cost, quick-turnaround, cancer screening and monitoring tool for companion animals (Nu.Q Vet), an adaption of its core nucleosome quantification (Nu.Q) platform on the human side. With supply and distribution deals with leading veterinary diagnostics players IDEXX and Heska already signed, Nu.Q Vet has the building blocks in place to evolve into a potential disrupter in the space.

17/01/2023 1 EN

Underlying

VolitionRX

See profile

US9286611077 NYSE MKT United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Sean Conroy

Other Reports on these Companies

Edison Investment Research

VolitionRx - Snaring sepsis, with early NETs detection

VolitionRx continues to make headway in growing a body of clinical evidence to build Nu.Q® NETs as a potential breakthrough tool in sepsis. These efforts, coupled with its CE mark in Europe, are a strong foundation in rapid and simplified sepsis detection that seeks to address the limitations and complexities of the current standard of care. Sepsis (immune-system triggered organ dysfunction) has a worrisome prevalence, affecting c 50 million per year with a mortality rate of c 20–25%, exceeding the combination of many leading cancers. Further, every hour of delayed treatment increases the chan...

February 8, 2024 February 8, 2024 1 EN

Edison Investment Research

VolitionRX - Unravelling the web of NETs in sepsis

VolitionRx is a clinical diagnostics company with a different perspective on immunoassay technology for the detection and monitoring of severe diseases in both humans and companion animals. Unlike sequential organ failure assessment (SOFA), which requires multiple physiological measurements, VolitionRx’s proprietary Nu.Q neutrophil extracellular traps (NETs) immunoassay technology takes a more direct route in a largely stale and fragmented market. This ability to rapidly diagnose and monitor patients supports numerous clinical use cases across specialties and most immediately addresses sepsis,...

August 15, 2022 August 15, 2022 1 EN

Datatec - FY24 underlying EPS more than doubles y-o-y

In a second more detailed trading update for FY24, Datatec confirmed revenue growth of 6% to $5.46bn, with Westcon International delivering excellent performance, Logicalis International having a strong H2 and Logicalis Latin America affected by difficult market conditions in Argentina and Brazil. The company also provided provisional EPS data, with reported EPS likely to come in ahead of our forecast and underlying EPS just below our forecast. We maintain our forecasts pending FY24 results on or around 27 May.

15h / 51m 15h / 51m 1 EN

Alison Turner

Alison Turner

Pan American Silver - La Arena divestment

Pan American Silver (PAAS) has announced a sale of the La Arena and La Arena II projects to Zijin Mining for US$245m in cash, US$50m in a contingent payment and a 1.5% NSR gold royalty. La Arena II is a copper and gold sulphide deposit that sits underneath the currently producing La Arena gold project. We view the transaction as positive for PAAS, given La Arena’s very short mine life, significant capex required to bring La Arena II into production and the fact that copper is not PAAS’s core commodity.

16h / 36m 16h / 36m 1 EN

Richard Williamson

Richard Williamson

SenSen Networks - Time to scale

SenSen’s Q324 results reflect the move to a lower cost base that provides a platform for future profitability. Minor delays to the National Heavy Vehicle Regulator (NHVR) contract affected Q3 but should not affect FY24 as most of the deployment is now complete. North American Smart Cities growth is gaining traction via partnerships, underpinning Q424 momentum alongside strong fuel theft solution uptake. Restructuring to drive a return to sustainable free cash flow is mostly complete but resulted in one-off costs. We revise down our FY24 forecasts assuming similar Q4 growth from a lower Q3 base...

19h / 51m 19h / 51m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

VolitionRx - Vetting the pet health opportunity

VolitionRx - Snaring sepsis, with early NETs detection

VolitionRX - Unravelling the web of NETs in sepsis

Datatec - FY24 underlying EPS more than doubles y-o-y

Pan American Silver - La Arena divestment

SenSen Networks - Time to scale

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe